# Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

> **NCT02511184** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 9 (actual)

## Conditions studied

- ALK-positive Advanced NSCLC

## Interventions

- **DRUG:** Crizotinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02511184
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Decision based on the low enrollment mainly due to high efficacy drugs available in 1st line ALK-positive NSCLC (eg alectinib), not due to any safety concerns
- **Last updated:** 2019-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511184, "Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02511184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*